Pasithea Therapeutics to Host Virtual Key Opinion Leader Event on NF1 Treatment

Article summary

Pasithea Therapeutics announced it will host a virtual key opinion leader event on November 4, 2026, to discuss the treatment landscape for neurofibromatosis type 1 (NF1) and the progress of its lead candidate, PAS-004.